Bluebird Gene Therapy Trial Shows Promising but Nuanced Results

Nov 5, 2015, 09:25 by Michael Croft

TheStreet | Bluebird Bio has released new interim results from its clinical trial of LentiGlobin gene therapy for beta-thalassemia and sickle cell disease, showing that it can wean patients off blood transfusions but that results are unexpectedly dependent on recipients' exact genotypes.

November 05, 2015 | Bluebird Bio has released new interim results from its clinical trial of LentiGlobin gene therapy for beta-thalassemia and sickle cell disease, showing that it can wean patients off blood transfusions but that results are unexpectedly dependent on recipients' exact genotypes. TheStreet